Replimune Group, Inc. (NASDAQ:REPL) Stock Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts have a “Moderate Buy” consensus on Replimune, with six Buy, one Strong Buy, one Hold, and two Sell ratings. Their average 12-month price target is $14.33, below the stock’s reported Friday opening price of $21.62.
• Replimune reported a quarterly loss of $0.54 per share, beating analyst expectations for a loss of $0.78 per share.
• Company insiders sold 100,624 shares worth about $1.45 million over the past three months; the reported sales by the CEO and chief accounting officer were to cover tax withholding on vested equity awards.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $14.33.

REPL has been the subject of several recent research reports. JPMorgan Chase & Co. boosted their price objective on Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, August 26th. Wolfe Research raised shares of Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th. Weiss Ratings lowered shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. Leerink Partners raised their price objective on shares of Replimune Group from $19.00 to $31.00 and gave the company an "outperform" rating in a report on Thursday, October 29th. Finally, Wall Street Zen upgraded Replimune Group from a "sell" rating to a "hold" rating in a research report on Saturday, October 31st.

Insider Activity

In other Replimune Group news, CAO Andrew Schwendenman sold 7,632 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $98,987.04. Following the completion of the sale, the chief accounting officer owned 99,425 shares of the company's stock, valued at $1,289,542.25. This represents a 7.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of Replimune Group stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. This trade represents a 5.26% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 100,624 shares of company stock worth $1,446,864. Corporate insiders own 5.40% of the company's stock.

Hedge Funds Weigh In On Replimune Group

A number of large investors have recently made changes to their positions in REPL. AXQ Capital LP grew its stake in Replimune Group by 4.1% in the second quarter. AXQ Capital LP now owns 27,121 shares of the company's stock worth $300,000 after purchasing an additional 1,056 shares in the last quarter. Walleye Capital LLC boosted its stake in shares of Replimune Group by 3.2% in the first quarter. Walleye Capital LLC now owns 71,592 shares of the company's stock valued at $548,000 after buying an additional 2,192 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Replimune Group by 30.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company's stock valued at $223,000 after purchasing an additional 4,050 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Replimune Group in the 3rd quarter valued at $64,000. Finally, Allworth Financial LP bought a new position in shares of Replimune Group in the 2nd quarter worth $62,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Stock Performance

NASDAQ REPL opened at $21.62 on Friday. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $21.91. The business has a fifty day moving average of $14.09 and a 200-day moving average of $9.67. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of -7.75 and a beta of 0.93.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.24. As a group, analysts predict that Replimune Group will post -2.40 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company's approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.